Cancer Research and Treatment

Original Articles

Pediatric cancer

Gonadal Function in Female Adolescent and Young Adult Survivors of Childhood Cancer: Hye Young Jin, Jun Ah Lee, Meerim Park, Hyeon Jin Park; Cancer Res Treat. 2023;55(3):992-1000. Published online January 31, 2023; DOI: https://doi.org/10.4143/crt.2022.1518

Purpose
Childhood cancer survivors (CCSs) are at risk for premature ovarian insufficiency (POI). The aim of this study is to evaluate ovarian function and associated health outcomes in female adolescent and young adult survivors of childhood cancer.
Materials and Methods
Sixty-nine female CCSs were enrolled. Medical records of CCSs were retrospectively reviewed. The subjects were categorized into three groups according to follicular stimulating hormone (FSH) levels (cutoff, 12, 40 IU/L). Anti-müllerian hormone (AMH) level less than 1 ng/mL was considered low AMH level.
Results
Of 69 subjects, 14 (20.3%) had POI and 14 (20.3%) had FSH levels between 12 and 40 IU/L. Forty-one of 69 (59.4%) had normal FSH levels. Pelvic irradiation and stem cell transplantation (SCT) were more frequently performed in subjects with POI (p=0.001 and p < 0.001). AMH levels were remarkably low when FSH levels were over 12 IU/L (p < 0.001). In multivariate analysis, cyclophosphamide equivalent dose and SCT were significant treatment factors for developing low AMH levels (p=0.005 and p=0.002, respectively). Total, low-density lipoprotein cholesterol and triglyceride were significantly different in three groups according to FSH levels (p=0.047, p=0.030, and p=0.045). Z-score of femur neck bone mineral density was significantly reduced when FSH levels were increased (p=0.011).
Conclusion
Gonadal dysfunction is common in CCSs. Gonadal function was associated with a few treatment factors known to increase the risk of POI. Regular monitoring of gonadal function is needed for better health outcomes.

Citations

Citations to this article as recorded by

Systematic Review of the Gonadotoxicity and Risk of Infertility of Soft Tissue Sarcoma Chemotherapies in Pre- and Postpubertal Females and Males
Marcel Steinmann, Anita Rietschin, Flavia Pagano, Tanya Karrer, Attila Kollár, Susanna Weidlinger, Michael von Wolff
Journal of Adolescent and Young Adult Oncology.2024; 13(6): 803. CrossRef
Bone Mineral Density in Survivors of Childhood Cancer: A Meta-Analysis
Lilly Velentza, Panagiotis Filis, Mari Wilhelmsson, Per Kogner, Nikolas Herold, Lars Sävendahl
Pediatrics.2024;[Epub] CrossRef

3,265 View
163 Download
2 Web of Science
2 Crossref

Epidemiologic and Clinical Outcomes of Pediatric Renal Tumors in Korea: A Retrospective Analysis of The Korean Pediatric Hematology and Oncology Group (KPHOG) Data: Kyung-Nam Koh, Jung Woo Han, Hyoung Soo Choi, Hyoung Jin Kang, Ji Won Lee, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Kyung Taek Hong, Jung Yoon Choi, Sung Han Kang, Hyery Kim, Ho Joon Im, Seung Min Hahn, Chuhl Joo Lyu, Hee-Jo Baek, Hoon Kook, Kyung Mi Park, Eu Jeen Yang, Young Tak Lim, Seongkoo Kim, Jae Wook Lee, Nack-Gyun Chung, Bin Cho, Meerim Park, Hyeon Jin Park, Byung-Kiu Park, Jun Ah Lee, Jun Eun Park, Soon Ki Kim, Ji Yoon Kim, Hyo Sun Kim, Youngeun Ma, Kyung Duk Park, Sang Kyu Park, Eun Sil Park, Ye Jee Shim, Eun Sun Yoo, Kyung Ha Ryu, Jae Won Yoo, Yeon Jung Lim, Hoi Soo Yoon, Mee Jeong Lee, Jae Min Lee, In-Sang Jeon, Hye Lim Jung, Hee Won Chueh, Seunghyun Won, the Korean Pediatric Hematology and Oncology Group (KPHOG); Cancer Res Treat. 2023;55(1):279-290. Published online August 11, 2022; DOI: https://doi.org/10.4143/crt.2022.073

Abstract PDF Supplementary Material PubReader ePub

Purpose
Renal tumors account for approximately 7% of all childhood cancers. These include Wilms tumor (WT), clear cell sarcoma of the kidney (CCSK), malignant rhabdoid tumor of the kidney (MRTK), renal cell carcinoma (RCC), congenital mesoblastic nephroma (CMN) and other rare tumors. We investigated the epidemiology of pediatric renal tumors in Korea.
Materials and Methods
From January 2001 to December 2015, data of pediatric patients (0–18 years) newly-diagnosed with renal tumors at 26 hospitals were retrospectively analyzed.
Results
Among 439 patients (male, 240), the most common tumor was WT (n=342, 77.9%), followed by RCC (n=36, 8.2%), CCSK (n=24, 5.5%), MRTK (n=16, 3.6%), CMN (n=12, 2.7%), and others (n=9, 2.1%). Median age at diagnosis was 27.1 months (range 0-225.5) and median follow-up duration was 88.5 months (range 0-211.6). Overall, 32 patients died, of whom 17, 11, 1, and 3 died of relapse, progressive disease, second malignant neoplasm, and treatment-related mortality. Five-year overall survival and event free survival were 97.2% and 84.8% in WT, 90.6% and 82.1% in RCC, 81.1% and 63.6% in CCSK, 60.3% and 56.2% in MRTK, and 100% and 91.7% in CMN, respectively (p < 0.001).
Conclusion
The pediatric renal tumor types in Korea are similar to those previously reported in other countries. WT accounted for a large proportion and survival was excellent. Non-Wilms renal tumors included a variety of tumors and showed inferior outcome, especially MRTK. Further efforts are necessary to optimize the treatment and analyze the genetic characteristics of pediatric renal tumors in Korea.

Citations

Citations to this article as recorded by

Congenital Mesoblastic Nephroma Mimic Wilms Tumor on 18F-FDG PET/CT and PET/MR
Wenzhu Hu, Chunxia Qin, Fuqiang Shao, Mengting Li, Xiaoli Lan
Clinical Nuclear Medicine.2024; 49(4): 353. CrossRef
Progress towards Therapies for Solid Renal Tumors in Children
洁林
Advances in Clinical Medicine.2024; 14(06): 245. CrossRef

6,957 View
188 Download
1 Web of Science
2 Crossref

Sarcoma

Incidence Patterns and Outcomes of Ewing Sarcoma in South Korea (1999-2017): A Retrospective Analysis Using Korea Central Cancer Registry Data: Jun Ah Lee, Jiwon Lim, Dayeon Park, Hye Young Jin, Meerim Park, Hyeon Jin Park, Jong Woong Park, June Hyuk Kim, Hyun Guy Kang, Young-Joo Won; Cancer Res Treat. 2022;54(2):590-596. Published online July 20, 2021; DOI: https://doi.org/10.4143/crt.2021.311

Abstract PDF PubReader ePub

Purpose
Due to low incidence, epidemiologic data of Ewing sarcoma in the Asian population are scarce. We aimed to examine the incidence pattern and outcome of patients with Ewing sarcoma in the Republic of Korea.
Materials and Methods
Data of patients with Ewing sarcoma diagnosed between 1999 and 2017 were obtained from the Korea Central Cancer Registry (KCCR). Incidence, clinical characteristics, and survival rates were analyzed and compared between different age groups.
Results
There were 788 cases (459 males, 329 females), with a median age at diagnosis of 20 years. The age-standardized rate of Ewing sarcoma was 1.01. The number of cases and incidence rates in each age group were as follows: children, 1.6; adolescents and young adults (AYA), 0.93; adults, 0.44; and elderly, 0.53. There were more male cases in children and the AYA group (p < 0.001). Extraskeletal tumors (p < 0.001), primary sites other than extremity (p=0.007), and presence of metastasis at diagnosis (p=0.031) were more frequent in the adults and elderly group. With a median survival time of 78 months, the 5-year overall survival (OS) rate of the entire cohort was 52%. Children fared best (5-year OS, 75%), and the 5-year OS of AYA patients (51%) approximated the OS of the entire cohort. A two-fold difference of 5-year OS was observed between adults and elderly patients (42% vs. 19%). On univariate and multivariate analyses, age ≥ 15 years and presence of metastasis were adverse prognostic factors.
Conclusion
This was the first epidemiologic study of Ewing sarcoma using the KCCR data. With a similar incidence to other Asian countries, the survival rate was slightly lower than that of Euro-American cases. Collaborative clinical studies are necessary to improve the outcome of Ewing sarcoma in low-incidence populations.

Citations

Citations to this article as recorded by

Twenty‐year outcome of prevalence, incidence, mortality and survival rate in patients with malignant bone tumors
Yao Xu, Fanqi Shi, Yanting Zhang, Mengfan Yin, Xiuxin Han, Jinyan Feng, Guowen Wang
International Journal of Cancer.2024; 154(2): 226. CrossRef
A Machine Learning-Based Predictive Model for Predicting Lymph Node Metastasis in Patients With Ewing’s Sarcoma
Wenle Li, Qian Zhou, Wencai Liu, Chan Xu, Zhi-Ri Tang, Shengtao Dong, Haosheng Wang, Wanying Li, Kai Zhang, Rong Li, Wenshi Zhang, Zhaohui Hu, Su Shibin, Qiang Liu, Sirui Kuang, Chengliang Yin
Frontiers in Medicine.2022;[Epub] CrossRef
TrkC, a novel prognostic marker, induces and maintains cell survival and metastatic dissemination of Ewing sarcoma by inhibiting EWSR1-FLI1 degradation
Min Soo Kim, Won Sung Lee, Hanki Lee, Wook Jin
Cell Death & Disease.2022;[Epub] CrossRef

6,008 View
120 Download
2 Web of Science
3 Crossref

Pediatric cancer

Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults: Hee Young Ju, Meerim Park, Jun Ah Lee, Hyeon Jin Park, Seog Yun Park, June Hyuk Kim, Hyun Guy Kang, Hee Chul Yang, Byung-Kiu Park; Cancer Res Treat. 2022;54(2):563-571. Published online June 14, 2021; DOI: https://doi.org/10.4143/crt.2021.178

Abstract PDF PubReader ePub

Purpose
No standard salvage regimen is available for relapsed or refractory sarcoma. We investigated the efficacy and toxicity of the vincristine, irinotecan, and temozolomide combination (VIT) for relapsed or refractory sarcomas of variable histology in children and young adults.
Materials and Methods
We retrospectively reviewed data from the relapsed or refractory sarcoma patients who were treated with VIT. The VIT protocol was given every 3 weeks as follows: vincristine, 1.5 mg/m² intravenously on day 1, irinotecan, 50 mg/m²/day intravenously on days 1-5, and temozolomide, 100 mg/m²/day orally on days 1-5.
Results
A total of 26 patients (12 males) with various sarcoma histology were included in the study. Most common diagnosis was rhabdomyosarcoma (n=8) followed by osteosarcoma (n=7). Median age at the start of VIT was 18.5 years (range, 2.0 to 39.9). VIT was delivered as 2nd to 7th line of treatment, with 4th line most common (9/26, 34.6%). Median number of VIT courses given was 3 (range, 1 to 18). Of the 25 evaluable patients, there was two partial response (PR) and 11 stable disease (SD) with an overall control rate (complete remission+PR+SD) of 52%. PR was seen in one (50%) of the two evaluable patients with Ewing sarcoma and one (14.3%) of the seven patients with osteosarcoma. Overall survival and progression-free survival rates were 79.3% and 33.9% at 1 year, and 45.5% and 25.4% at 2 years, respectively. There was no treatment-related mortality.
Conclusion
The VIT regimen was effective and relatively safe in our cohort of sarcoma patients.

Citations

Citations to this article as recorded by

MGMT protein expression is a reliable predictive biomarker for temozolomide‐containing chemotherapy in osteosarcoma
Yoshinori Uchihara, Katsutsugu Umeda, Yosuke Yamada, Hiroaki Ito, Keiji Tasaka, Kiyotaka Isobe, Ryo Akazawa, Naoko Kawabata, Satoshi Saida, Itaru Kato, Hidefumi Hiramatsu, Takashi Noguchi, Akio Sakamoto, Yoshiki Arakawa, Ayumu Arakawa, Nobuyuki Yamamoto,
Cancer Science.2024; 115(10): 3394. CrossRef
Anlotinib combined with radiotherapy and chemotherapy for recurrent pelvic osteosarcoma treatment: a case report and literature review
Qian Chen, Kai Zheng, Ming Xu, Ning Yan, Gong Hai, Xiuchun Yu
Frontiers in Oncology.2023;[Epub] CrossRef
Irinotecan/temozolomide/vincristine

Reactions Weekly.2022; 1910(1): 267. CrossRef
Acetylenic Synthetic Betulin Derivatives Inhibit Akt and Erk Kinases Activity, Trigger Apoptosis and Suppress Proliferation of Neuroblastoma and Rhabdomyosarcoma Cell Lines
Sylwia K. Król, Ewa Bębenek, Magdalena Dmoszyńska-Graniczka, Adrianna Sławińska-Brych, Stanisław Boryczka, Andrzej Stepulak
International Journal of Molecular Sciences.2021; 22(22): 12299. CrossRef

6,384 View
368 Download
5 Web of Science
4 Crossref

Central nervous system

Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System in Children under the Age of 3 Years: Meerim Park, Jung Woo Han, Seung Min Hahn, Jun Ah Lee, Joo-Young Kim, Sang Hoon Shin, Dong-Seok Kim, Hong In Yoon, Kyung Taek Hong, Jung Yoon Choi, Hyoung Jin Kang, Hee Young Shin, Ji Hoon Phi, Seung-Ki Kim, Ji Won Lee, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Do Hoon Lim, Hyung Jin Shin, Hyery Kim, Kyung-Nam Koh, Ho Joon Im, Seung Do Ahn, Young-Shin Ra, Hee-Jo Baek, Hoon Kook, Tae-Young Jung, Hyoung Soo Choi, Chae-Yong Kim, Hyeon Jin Park, Chuhl Joo Lyu; Cancer Res Treat. 2021;53(2):378-388. Published online October 28, 2020; DOI: https://doi.org/10.4143/crt.2020.756

Abstract PDF PubReader ePub

Purpose
Atypical teratoid/rhabdoid tumor (ATRT) is a highly aggressive malignancy with peak incidence in children aged less than 3 years. Standard treatment for central nervous system ATRT in children under the age of 3 years have not been established yet. The objective of this study was to analyze characteristics and clinical outcomes of ATRT in children aged less than 3 years.
Materials and Methods
A search of medical records from seven centers was performed between January 2005 and December 2016.
Results
Forty-three patients were enrolled. With a median follow-up of 90 months, 27 patients (64.3%) showed at least one episode of disease progression (PD). The first date of PD was at 160 days after diagnosis. The 1- and 3-year progression-free survivals (PFS) were 51.2% and 28.5%, respectively. The 1- and 3-year overall survivals were 61.9% and 38.1%, respectively. The 3-year PFS was improved from 0% in pre-2011 to 47.4% in post-2011. Excluding one patient who did not receive any further therapy after surgery, 27 patients died due to PD (n=21), treatment-related toxicity (n=5), or unknown cause (n=1). In univariate analysis, factors associated with higher 3-year PFS were no metastases, diagnosis after 2011, early adjuvant radiotherapy, and high-dose chemotherapy (HDCT). In multivariate analysis, the use of HDCT and adjuvant radiotherapy remained significant prognostic factors for PFS (both p < 0.01).
Conclusion
Aggressive therapy including early adjuvant radiotherapy and HDCT could be considered to improve outcomes of ATRT in children under the age of 3 years.

Citations

Citations to this article as recorded by

Supratentorial ATRT in a young Infant: Expanding the diagnostic spectrum beyond medulloblastoma
Ali Msheik, Mohamad Aoun, Youssef Fares
Interdisciplinary Neurosurgery.2024; 35: 101857. CrossRef
Radiation Therapy Plays an Important Role in the Treatment of Atypical Teratoid/Rhabdoid Tumors: Analysis of the EU-RHAB Cohorts and Their Precursors
Sabine Frisch, Hanna Libuschewski, Sarah Peters, Joachim Gerß, Katja von Hoff, Rolf-Dieter Kortmann, Karolina Nemes, Stefan Rutkowski, Martin Hasselblatt, Torsten Pietsch, Michael C. Frühwald, Beate Timmermann
International Journal of Radiation Oncology*Biology*Physics.2024; 119(4): 1147. CrossRef
An adult with recurrent atypical teratoid rhabdoid tumor of the spine
Antoinette J Charles, Vanessa L Smith, C Rory Goodwin, Margaret O Johnson
CNS Oncology.2024;[Epub] CrossRef
Dynamic Survival Risk Prognostic Model and Genomic Landscape for Atypical Teratoid/Rhabdoid Tumors: A Population-Based, Real-World Study
Sihao Chen, Yi He, Jiao Liu, Ruixin Wu, Menglei Wang, Aishun Jin
Cancers.2024; 16(5): 1059. CrossRef
ESTRO-SIOPE guideline: Clinical management of radiotherapy in atypical teratoid/rhabdoid tumors (AT/RTs)
Beate Timmermann, Claire Alapetite, Karin Dieckmann, Rolf-Dieter Kortmann, Yasmin Lassen-Ramshad, John H. Maduro, Monica Ramos Albiac, Umberto Ricardi, Damien C. Weber
Radiotherapy and Oncology.2024; 196: 110227. CrossRef
Development and epigenetic regulation of Atypical teratoid/rhabdoid tumors in the context of cell-of-origin and halted cell differentiation
Laura Huhtala, Goktug Karabiyik, Kirsi J Rautajoki
Neuro-Oncology Advances.2024;[Epub] CrossRef
Metabolic profiling of patient-derived organoids reveals nucleotide synthesis as a metabolic vulnerability in malignant rhabdoid tumors
Marjolein M.G. Kes, Francisco Morales-Rodriguez, Esther A. Zaal, Terezinha de Souza, Natalie Proost, Marieke van de Ven, Marry M. van den Heuvel-Eibrink, Jeroen W.A. Jansen, Celia R. Berkers, Jarno Drost
Cell Reports Medicine.2024; : 101878. CrossRef
Comparative treatment results of children with atypical teratoid/rhabdoid tumor of the central nervous system in the younger age group
L. V. Olkhova, O. G. Zheludkova, L. S. Zubarovskaya, A. S. Levashov, A. Yu. Smirnova, Yu. V. Dinikina, Yu. V. Kushel, A. G. Melikyan, S. K. Gorelyshev, M. V. Ryzhova, Yu. Yu. Trunin, A. G. Gevorgyan, O. B. Polushkina, V. E. Popov, L. P. Privalova, N. B. Y
Russian Journal of Pediatric Hematology and Oncology.2023; 10(1): 11. CrossRef
Current Challenges of Asian National Children's Cancer Study Groups on Behalf of Asian Pediatric Hematology and Oncology Group
Chi-kong Li, Purna Kurkure, Ramandeep Singh Arora, Bow Wen Chen, Kirill Kirgizov, Yasuhiro Okamoto, Panya Seksarn, Yongmin Tang, Keon Hee Yoo, Bharat Agarwal, Godfrey C.F. Chan, Rashmi Dalvi, Hiroki Hori, Muhammad Saghir Khan, Alice Yu, Akira Nakagawara
JCO Global Oncology.2023;[Epub] CrossRef
Survival and Malignant Transformation of Pineal Parenchymal Tumors: A 30-Year Retrospective Analysis in a Single-Institution
Tae-Hwan Park, Seung-Ki Kim, Ji Hoon Phi, Chul-Kee Park, Yong Hwy Kim, Sun Ha Paek, Chang-Hyun Lee, Sung-Hye Park, Eun Jung Koh
Brain Tumor Research and Treatment.2023; 11(4): 254. CrossRef
Atypical Teratoid/Rhabdoid Tumor in Taiwan: A Nationwide, Population-Based Study
Yen-Lin Liu, Min-Lan Tsai, Chang-I Chen, Noi Yar, Ching-Wen Tsai, Hsin-Lun Lee, Chia-Chun Kuo, Wan-Ling Ho, Kevin Li-Chun Hsieh, Sung-Hui Tseng, James S. Miser, Chia-Yau Chang, Hsi Chang, Wen-Chang Huang, Tai-Tong Wong, Alexander T. H. Wu, Yu-Chun Yen
Cancers.2022; 14(3): 668. CrossRef
Atypical Teratoid Rhabdoid Tumor: A Possible Oriented Female Pathology?
Cinzia Baiano, Rosa Della Monica, Raduan Ahmed Franca, Maria Laura Del Basso De Caro, Luigi Maria Cavallo, Lorenzo Chiariotti, Tamara Ius, Emmanuel Jouanneau, Teresa Somma
Frontiers in Oncology.2022;[Epub] CrossRef
Clinical predictors of survival for patients with atypical teratoid/rhabdoid tumors
Vismaya S. Bachu, Pavan Shah, Adrian E. Jimenez, Adham M. Khalafallah, Jignesh Tailor, Debraj Mukherjee, Alan R. Cohen
Child's Nervous System.2022; 38(7): 1297. CrossRef
Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors
Yukitomo Ishi, Yongzhan Zhang, Ali Zhang, Takahiro Sasaki, Andrea Piunti, Amreena Suri, Jun Watanabe, Kouki Abe, Xingyao He, Hiroaki Katagi, Pankaj Bhalla, Manabu Natsumeda, Lihua Zou, Ali Shilatifard, Rintaro Hashizume
Molecular Cancer Therapeutics.2022; 21(5): 715. CrossRef
Molecular targeted therapies for pediatric atypical teratoid/rhabdoid tumors
Chang Zhang, Hao Li
Pediatric Investigation.2022; 6(2): 111. CrossRef
The results of multicenter treatment of atypical teratoid/rhabdoid tumors of the central nervous system in children under 3 years
L. V. Olkhova, O. G. Zheludkova, L. S. Zubarovskaya, A. Yu. Smirnova, Yu. V. Dinikina, Yu. V. Kushel, A. G. Melikyan, S. K. Gorelyshev, M. V. Ryzhova, Yu. Yu. Trunin, E. I. Shults, A. G. Gevorgyan, S. V. Gorbatykh, A. N. Kislyakov, V. E. Popov, L. P. Priv
Pediatric Hematology/Oncology and Immunopathology.2021; 20(2): 121. CrossRef

8,993 View
300 Download
13 Web of Science
16 Crossref

General

Cancer Incidence and Survival among Adolescents and Young Adults in Korea: An Update for 2016: Meerim Park, Jiwon Lim, Jun Ah Lee, Byung Kiu Park, Kyu-Won Jung, Young-Joo Won, Hyeon Jin Park; Cancer Res Treat. 2021;53(1):32-44. Published online October 5, 2020; DOI: https://doi.org/10.4143/crt.2020.644

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study investigated the incidence and relative survival rates (RSRs) for cancers among adolescents and young adults (AYAs) aged 15-39 years between 1993 and 2016 in Korea
Materials and Methods
Data from the Korea Central Cancer Registry were used to calculate percent distributions, age-specific incidence rates, age-standardized incidence rates (ASRs) per million, annual percent changes (APCs), average APCs, and RSRs for cancers diagnosed in AYAs.
Results
ASR of all cancers among AYAs was 654.5 per million. The largest diagnosed group of cancers was carcinomas (almost 80%). Crude incidence increased with age, from 170.4 per million for those aged 15-19 years to 1,639.8 per million for those aged 35-39 years. ASR increased from 414.8 per million to 820.4 per million, with an APC of 9.0%. The incidence of thyroid carcinoma showed the most rapid increment (APC, 14.0%), followed by non-Hodgkin lymphoma (APC, 13.4%). The 5-year RSR among AYAs significantly improved from 62.1% to 90.8%. Survival improvement in AYAs was higher than that in children but lower than that in older adults (APC, 2.1% vs. 1.9% vs. 3.1%). The most marked survival improvement was found for leukemia and lymphoma. Astrocytoma, rhabdomyosarcoma, and carcinoma of the trachea, bronchus, and lung had a 5-year RSR of < 50%.
Conclusion
There was an improvement in cancer survivals in AYAs, comparable to that achieved in children. However, survivals in several cancer types do not appear to be improving. Further research focusing on the epidemiology and therapeutic strategies for cancers in AYAs is needed.

Citations

Citations to this article as recorded by

Research progress in the application of radiotherapy in the treatment of pediatric tumors
Z-H. Wang, Y. Liu, J-Q. Guo, H-L. Liang, W-W. Zhi
International Journal of Radiation Research.2024; 22(1): 65. CrossRef
Racial disparities in the incidence and survival outcomes in diffuse large B‐cell lymphoma in adolescents and young adults
Mustafa Wasifuddin, Nosakhare Paul Ilerhunmwuwa, Henry Becerra, Narek Hakobyan, Neharika Shrestha, Ifeanyi Nnamdi Uche, Htet Lin, Hesham Abowali, Jin Zheng, Ruchi Yadav, Akriti Pokhrel, Ladan Enayati, Mitchell Hare, Rohan Hehr, Khrystyna Kozii, Bulat Giba
European Journal of Haematology.2024; 113(4): 454. CrossRef
Perception of Korean healthy adolescents on cancer and adolescent cancer survivors: a cross-sectional survey
Min Kyung Hyun, Yeonseung Lee, Hyun Jeong Lee, Young Ae Kim
BMC Public Health.2024;[Epub] CrossRef
Psychometric evaluation of the spiritual perspective scale for adolescents and young adults with cancer
Chin-Mi Chen, Heeyeon Son, Yvonne Yueh-Feng Lu, Li-Min Wu
Asia-Pacific Journal of Oncology Nursing.2024; 11(11): 100594. CrossRef
Development and evaluation of the feasibility, validity, and reliability of a screening tool for determining distress and supportive care needs of adolescents and young adults with cancer in Japan
Takatoshi Hirayama, Maiko Fujimori, Yuko Yanai, Hiroto Ishiki, Akie Shindo, Moeko Tanaka, Tomomi Kobayashi, Rebekah Kojima, Eriko Satomi
Palliative and Supportive Care.2023; 21(4): 677. CrossRef
Five-year Survival Trends for Young Adult Cancers Diagnosed from 2002 to 2014 in Taiwan and the United States
Yu-Han Tsai, Yu-Tung Teng, Tai-Chuan Kuan, Jason J. Liu
Cancer Epidemiology, Biomarkers & Prevention.2023; 32(6): 834. CrossRef
Global and regional trends in incidence and mortality of female breast cancer and associated factors at national level in 2000 to 2019
Chenyu Luo, Na Li, Bin Lu, Jie Cai, Ming Lu, Yuhan Zhang, Hongda Chen, Min Dai
Chinese Medical Journal.2022; 135(1): 42. CrossRef
Fertility‐sparing surgery for early‐stage cervical cancer: A case series study on the efficacy and feasibility of cervical conization followed by pelvic lymphadenectomy
Mayuko Yamamoto, Takeshi Motohara, Yutaka Iwagoi, Shingo Tayama, Hironori Tashiro, Eiji Kondoh, Hidetaka Katabuchi
Journal of Obstetrics and Gynaecology Research.2022; 48(6): 1444. CrossRef
Young adult cancer incidence trends in Taiwan and the U.S. from 2002 to 2016
Hsin Wang, Yu-Han Tsai, Yaa-Hui Dong, Jason J. Liu
Cancer Epidemiology.2022; 78: 102144. CrossRef
Osteosarcoma in Adolescents and Young Adults
Jun Ah Lee, Jiwon Lim, Hye Young Jin, Meerim Park, Hyeon Jin Park, Jong Woong Park, June Hyuk Kim, Hyun Guy Kang, Young-Joo Won
Cells.2021; 10(10): 2684. CrossRef

8,144 View
212 Download
12 Web of Science
10 Crossref

Case Report

Hyperammonemic Encephalopathy Mimicking Ornithine Transcarbamylase Deficiency in Fibrolamellar Hepatocellular Carcinoma: Successful Treatment with Continuous Venovenous Hemofiltration and Ammonia Scavengers: Jeong-Seon Lee, Hye Young Jin, Jung Min Ko, Seoung Hoon Kim, Nayoung Han, Byung Kiu Park, Meerim Park, Hyeon Jin Park, Jun Ah Lee; Cancer Res Treat. 2021;53(1):283-288. Published online September 7, 2020; DOI: https://doi.org/10.4143/crt.2020.575

Abstract PDF PubReader ePub

Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare liver cancer affecting adolescents and young adults without any pre existing liver disease. Hyperammonemic encephalopathy (HAE) is a serious paraneoplastic syndrome, and several cases of HAE have been reported in patients with FLHCC. This condition is rare; hence, there are currently no management guidelines for cancer-related HAE. Herein, we report a case of an 18-year-old man with advanced FLHCC who developed HAE during the first course of chemotherapy consisting of cisplatin, doxorubicin, 5-fluorouracil, and interferon-α. He was successfully treated with continuous venovenous hemofiltration, sodium benzoate, sodium phenylbutyrate, and amino acid supplementation for HAE. After the second course of chemotherapy, he underwent surgery, and thereafter, his ammonia levels were normal without any ammonia scavenger therapy. Treatments for HAE described here will be helpful for this rare, but serious metabolic complication of FLHCC and could partially applied to HAE related to any malignancies.

Citations

Citations to this article as recorded by

Mitochondrial targets in hyperammonemia: Addressing urea cycle function to improve drug therapies
Marco F. Moedas, Ricardo J.M. Simões, Margarida F.B. Silva
Biochemical Pharmacology.2024; 222: 116034. CrossRef
Fibroadenoma Intracanalicular Hipercelular: uma revisão de literatura e relato de 5 casos
Isadora Benevides Silva Gondim Nascimento, Roberta Pereira Guerra Pedra, Amanda Veloso Teixeira, Maria Isabel Teles Nogueira, Kaio Henrique Oliveira Pontes
Journal Archives of Health.2024; 5(3): e1860. CrossRef
Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinoma
Solomon N. Levin, Michael D. Tomasini, James Knox, Mahsa Shirani, Bassem Shebl, David Requena, Jackson Clark, Søren Heissel, Hanan Alwaseem, Rodrigo Surjan, Ron Lahasky, Henrik Molina, Michael S. Torbenson, Barbara Lyons, Rachael D. Migler, Philip Coffino
Science Advances.2023;[Epub] CrossRef
WITHDRAWN: Refractory Hyperammonemic encephalopathy in Fibrolamellar hepatocellular carcinoma, a case report and literature review
Arwa Ahmed, Fateen Ata, Mohammed Gaber, Mahir Petkar, Ahmed Mahfouz, Peter Schirmacher, Sara Musa, Ahmed Hashim
Current Problems in Cancer: Case Reports.2022; : 100141. CrossRef
Refractory Hyperammonemic encephalopathy in Fibrolamellar hepatocellular carcinoma, a case report and literature review
Arwa Ahmed, Fateen Ata, Mohammed Gaber, Mahir Petkar, Ahmed Mahfouz, Peter Schirmacher, Sara Musa, Ahmed Hashim
Current Problems in Cancer.2022; 46(3): 100847. CrossRef
Clinical and biochemical footprints of inherited metabolic diseases. VIII. Neoplasias
Teodoro Jerves, Nenad Blau, Carlos R. Ferreira
Molecular Genetics and Metabolism.2022; 136(2): 118. CrossRef
Paraneoplastic syndromes in hepatocellular carcinoma: a review
Yuki Ong, Cheong Wei Terence Huey, Vishalkumar Girishchandra Shelat
Expert Review of Gastroenterology & Hepatology.2022; 16(5): 449. CrossRef
Collagen Remodeling along Cancer Progression Providing a Novel Opportunity for Cancer Diagnosis and Treatment
Kena Song, Zhangqing Yu, Xiangyang Zu, Guoqiang Li, Zhigang Hu, Yun Xue
International Journal of Molecular Sciences.2022; 23(18): 10509. CrossRef
Fibrolamellar carcinoma: An entity all its own
Allison F. O'Neill, Alanna J. Church, Antonio R. Perez-Atayde, Raja Shaikh, Karen J. Marcus, Khashayar Vakili
Current Problems in Cancer.2021; 45(4): 100770. CrossRef
Severe digital ischemia coexists with thrombocytopenia in malignancy-associated antiphospholipid syndrome: A case report and review of literature
Jia-Lei Chen, Xi Yu, Rong Luo, Ming Liu
World Journal of Clinical Cases.2021; 9(36): 11457. CrossRef
Antineoplastics/sodium-benzoate

Reactions Weekly.2020; 1825(1): 46. CrossRef

6,766 View
190 Download
9 Web of Science
11 Crossref

Original Article

Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients: Hyery Kim, Hyoung Jin Kang, Kyung Duk Park, Kyung-Nam Koh, Ho Joon Im, Jong Jin Seo, Jae Wook Lee, Nack-Gyun Chung, Bin Cho, Hack Ki Kim, Jae Min Lee, Jeong Ok Hah, Jun Ah Lee, Young Ho Lee, Sang Kyu Park, Hee Jo Baek, Hoon Kook, Ji Yoon Kim, Heung Sik Kim, Hwang Min Kim, Hee Won Chueh, Meerim Park, Hoi Soo Yoon, Mee Jeong Lee, Hyoung Soo Choi, Hyo Seop Ahn, Yoshifumi Kawano, Ji Won Park, Seokyung Hahn, Hee Young Shin; Cancer Res Treat. 2019;51(1):357-367. Published online May 14, 2018; DOI: https://doi.org/10.4143/crt.2017.457

Abstract PDF Supplementary Material PubReader ePub

Purpose
Dexrazoxane has been used as an effective cardioprotector against anthracycline cardiotoxicity. This study intended to analyze cardioprotective efficacy and secondary malignancy development, and elucidate risk factors for secondary malignancies in dexrazoxane-treated pediatric patients.
Materials and Methods
Data was collected from 15 hospitals in Korea. Patients who received any anthracyclines, and completed treatment without stem cell transplantation were included. For efficacy evaluation, the incidence of cardiac events and cardiac event-free survival rates were compared. Data about risk factors of secondary malignancies were collected.
Results
Data of total 1,453 cases were analyzed; dexrazoxane with every anthracyclines group (D group, 1,035 patients) and no dexrazoxane group (non-D group, 418 patients). Incidence of the reported cardiac events was not statistically different between two groups; however, the cardiac event-free survival rate of patients with more than 400 mg/m² of anthracyclines was significantly higher in D group (91.2% vs. 80.1%, p=0.04). The 6-year cumulative incidence of secondary malignancy was not different between both groups after considering follow-up duration difference (non-D, 0.52%±0.37%; D, 0.60%±0.28%; p=0.55). The most influential risk factor for secondary malignancy was the duration of anthracycline administration according to multivariate analysis.
Conclusion
Dexrazoxane had an efficacy in lowering cardiac event-free survival rates in patients with higher cumulative anthracyclines. As a result of multivariate analysis for assessing risk factors of secondary malignancy, the occurrence of secondary malignancy was not related to dexrazoxane administration.

Citations

Citations to this article as recorded by

Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage
Veronika Keresteš, Jan Kubeš, Lenka Applová, Petra Kollárová, Olga Lenčová-Popelová, Iuliia Melnikova, Galina Karabanovich, Mushtaq M Khazeem, Hana Bavlovič-Piskáčková, Petra Štěrbová-Kovaříková, Caroline A Austin, Jaroslav Roh, Martin Štěrba, Tomáš Šimůn
Toxicological Sciences.2024; 198(2): 288. CrossRef
Circ-0006332 stimulates cardiomyocyte pyroptosis via the miR-143/TLR2 axis to promote doxorubicin-induced cardiac damage
Ping Zhang, Yuanyuan Liu, Yuliang Zhan, Pengtao Zou, Xinyong Cai, Yanmei Chen, Liang Shao
Epigenetics.2024;[Epub] CrossRef
Pediatric Cardio-Oncology: Screening, Risk Stratification, and Prevention of Cardiotoxicity Associated with Anthracyclines
Xiaomeng Liu, Shuping Ge, Aijun Zhang
Children.2024; 11(7): 884. CrossRef
Efficacy of Dexrazoxane in Cardiac Protection in Pediatric Patients Treated With Anthracyclines
Parya Rahimi, Behsheed Barootkoob, Ahmed ElHashash, Arun Nair
Cureus.2023;[Epub] CrossRef
Inducing a Proinflammatory Response with Bioengineered Yeast Vacuoles with TLR2-Binding Peptides (VacT2BP) as a Drug Carrier for Daunorubicin Delivery
Wooil Choi, Woo-Ri Shin, Yang-Hoon Kim, Jiho Min
ACS Applied Materials & Interfaces.2023; 15(35): 41258. CrossRef
Circulating Biomarkers for Monitoring Chemotherapy-Induced Cardiotoxicity in Children
Luigia Meo, Maria Savarese, Carmen Munno, Peppino Mirabelli, Pia Ragno, Ornella Leone, Mariaevelina Alfieri
Pharmaceutics.2023; 15(12): 2712. CrossRef
Hyperhomocysteinemia as a Link of Chemotherapy-Related Endothelium Impairment
Ashot Avagimyan
Current Problems in Cardiology.2022; 47(10): 100932. CrossRef
Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group
Eric J. Chow, Richard Aplenc, Lynda M. Vrooman, David R. Doody, Yuan‐Shung V. Huang, Sanjeev Aggarwal, Saro H. Armenian, K. Scott Baker, Smita Bhatia, Louis S. Constine, David R. Freyer, Lisa M. Kopp, Wendy M. Leisenring, Barbara L. Asselin, Cindy L. Schw
Cancer.2022; 128(4): 788. CrossRef
Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group
Esmée C de Baat, Elvira C van Dalen, Renée L Mulder, Melissa M Hudson, Matthew J Ehrhardt, Frederike K Engels, Elizabeth A M Feijen, Heynric B Grotenhuis, Jan M Leerink, Livia Kapusta, Gertjan J L Kaspers, Remy Merkx, Luc Mertens, Roderick Skinner, Wim J
The Lancet Child & Adolescent Health.2022; 6(12): 885. CrossRef
Cardiotoxicity After Anthracycline Chemotherapy for Childhood Cancer in a Multiethnic Asian Population
Varen Zhi Zheng Tan, Nicole Min Chan, Wai Lin Ang, Soe Nwe Mya, Mei Yoke Chan, Ching Kit Chen
Frontiers in Pediatrics.2021;[Epub] CrossRef
Early-onset Cardiotoxicity assessment related to anthracycline in children with leukemia. A Prospective Study
Adriana Linares Ballesteros, Roy Sanguino Lobo, Juan Camilo Villada Valencia, Oscar Arévalo Leal, Diana Constanza Plazas Hernández, Nelson Aponte Barrios, Iván Perdomo Ramírez
Colombia Medica.2021; 52(1): e2034542. CrossRef
Mechanisms and Insights for the Development of Heart Failure Associated with Cancer Therapy
Claire Fraley, Sarah A. Milgrom, Lavanya Kondapalli, Matthew R. G. Taylor, Luisa Mestroni, Shelley D. Miyamoto
Children.2021; 8(9): 829. CrossRef
Dantrolene Attenuates Cardiotoxicity of Doxorubicin Without Reducing its Antitumor Efficacy in a Breast Cancer Model
Valentina K. Todorova, Eric R. Siegel, Yihong Kaufmann, Asangi Kumarapeli, Aaron Owen, Jeanne Y. Wei, Issam Makhoul, V. Suzanne Klimberg
Translational Oncology.2020; 13(2): 471. CrossRef
Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase IIβ Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity
Petra Kollárová-Brázdová, Anna Jirkovská, Galina Karabanovich, Zuzana Pokorná, Hana Bavlovič Piskáčková, Eduard Jirkovský, Jan Kubeš, Olga Lenčová-Popelová, Yvona Mazurová, Michaela Adamcová, Veronika Skalická, Petra Štěrbová-Kovaříková, Jaroslav Roh, Tom
The Journal of Pharmacology and Experimental Therapeutics.2020; 373(3): 402. CrossRef
Anthracyclines/cyclophosphamide/etoposide

Reactions Weekly.2019; 1741(1): 28. CrossRef
Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series
Sarju Ganatra, Anju Nohria, Sachin Shah, John D. Groarke, Ajay Sharma, David Venesy, Richard Patten, Krishna Gunturu, Corrine Zarwan, Tomas G. Neilan, Ana Barac, Salim S. Hayek, Sourbha Dani, Shantanu Solanki, Syed Saad Mahmood, Steven E. Lipshultz
Cardio-Oncology.2019;[Epub] CrossRef
Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
Neha Bansal, M. Jacob Adams, Sarju Ganatra, Steven D. Colan, Sanjeev Aggarwal, Rudolf Steiner, Shahnawaz Amdani, Emma R. Lipshultz, Steven E. Lipshultz
Cardio-Oncology.2019;[Epub] CrossRef
Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies – Part 2
Antonis A. Manolis, Theodora A. Manolis, Dimitri P. Mikhailidis, Antonis S. Manolis
Expert Opinion on Drug Safety.2018; 17(9): 893. CrossRef

10,116 View
333 Download
19 Web of Science
18 Crossref

Case Report

Severe Hepatic Sinusoidal Obstruction Syndrome in a Child Receiving Vincristine, Actinomycin-D, and Cyclophosphamide for Rhabdomyosarcoma: Successful Treatment with Defibrotide: Aery Choi, Young Kyung Kang, Sewon Lim, Dong Ho Kim, Jung Sub Lim, Jun Ah Lee; Cancer Res Treat. 2016;48(4):1443-1447. Published online March 30, 2016; DOI: https://doi.org/10.4143/crt.2016.096

Abstract PDF PubReader ePub

Hepatic sinusoidal obstruction syndrome (SOS) is a life-threatening syndrome that generally occurs as a complication after hematopoietic stem cell transplantation or, less commonly, after conventional chemotherapy. Regarding SOS in rhabdomyosarcoma patients who received conventional chemotherapy, the doses of chemotherapeutic agents are associated with the development of SOS. Several cases of SOS in rhabdomyosarcoma patients after receiving chemotherapy with escalated doses of cyclophosphamide have been reported. Here, we report on a 9-year-old female with rhabdomyosarcoma who developed severe SOS after receiving chemotherapy consisting of vincristine, actinomycin-D, and a moderate dose of cyclophosphamide. She was treated successfully with defibrotide without sequelae to the liver.

Citations

Citations to this article as recorded by

Drug-induced hepatic sinusoidal obstruction syndrome: current advances and future perspectives
Zaoqin Yu, Wei Li, Cheng Tian, Yan Cao, Chengliang Zhang
Archives of Toxicology.2024;[Epub] CrossRef
Treatment of Sinusoidal Obstruction Syndrome With Defibrotide in Pediatric Cancer Patients Following Nontransplant-associated Chemotherapy: A Case Report and Review of the Literature
Marc R. Lawrence, Mylène Bassal, Raveena Ramphal, Donna L. Johnston
Journal of Pediatric Hematology/Oncology.2022; 44(3): e788. CrossRef
Indispensable role of microbes in anticancer drugs and discovery trends
Ridam Kapoor, Anamika Saini, Deepika Sharma
Applied Microbiology and Biotechnology.2022; 106(13-16): 4885. CrossRef
Caspase inhibitor z-VAD-FMK increases the survival of hair cells after Actinomycin-D-induced damage in vitro
Huimin Chang, Fei Sun, Keyong Tian, Weilong Wang, Ke Zhou, Dingjun Zha, Jianhua Qiu
Neuroscience Letters.2020; 732: 135089. CrossRef
Adjuvant recombinant thrombomodulin therapy for hepatopathy induced by vincristine, actinomycin D, and cyclophosphamide in pediatric rhabdomyosarcoma: A case report
Tetsuko Kobayashi, Maiko Noguchi, Hideki Nakayama, Reiji Fukano, Shouichi Ohga
Molecular and Clinical Oncology.2019;[Epub] CrossRef
“Pre‐emptive strike”—the case for early treatment of hepatic sinusoidal obstruction syndrome with defibrotide
Revathi Rajagopal, Marianne B. Phillips, Nicholas G. Gottardo
Pediatric Blood & Cancer.2018;[Epub] CrossRef
Cyclophosphamide/dactinomycin/vincristine

Reactions Weekly.2017; 1637(1): 75. CrossRef

10,594 View
207 Download
7 Web of Science
7 Crossref

Original Articles

Epidermal Growth Factor Receptor: Is It a Feasible Target for the Treatment of Osteosarcoma?: Jun Ah Lee, Yunmi Ko, Dong Ho Kim, Jung Sub Lim, Chang-Bae Kong, Wan Hyeong Cho, Dae-Geun Jeon, Soo-Yong Lee, Jae-Soo Koh; Cancer Res Treat. 2012;44(3):202-209. Published online September 30, 2012; DOI: https://doi.org/10.4143/crt.2012.44.3.202

Abstract PDF PubReader ePub

PURPOSE
Features of epidermal growth factor receptor (EGFR) expression in osteosarcoma and in vitro efficacies of EGFR inhibitors against osteosarcoma cells were evaluated.
MATERIALS AND METHODS
Thirty biopsy samples of osteosarcoma patients were retrospectively analyzed for EGFR protein expression by immunohistochemistry. Relationships between EGFR expression and clinicopathologic characteristics and treatment outcomes were evaluated. Four osteosarcoma cell lines were analyzed for EGFR and p-EGFR expression by western blotting. Efficacies of gefitinib and BIBW2992 on osteosarcoma cells were evaluated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Tyrosine kinase domains in exons 18 to 21 were sequenced and gene expression analyses of EGFR and PTEN were performed in four osteosarcoma cell lines.
RESULTS
EGFR protein was expressed in 27 (90%) samples (6 low, 12 intermediate, 9 high) and in three cell lines. Intermediate or high staining for EGFR was related to a tumor volume<150 mL (p<0.001) and histologic subtype other than osteoblastic type (p=0.03). However, EGFR expression was not associated with histologic response to preoperative chemotherapy or survival. Gefitinib and BIBW 2992 did not have any significant inhibitory effect on cell viabilities. DNA sequencing analysis revealed three osteosarcoma cell lines have single base changes at codon 2361 of exon 20 (G to A), without affecting translation results. Furthermore, no mutation was found to be associated with constitutive EGFR activation.
CONCLUSION
In the present study, gefitinib and BIBW2992 were not effective against osteosarcoma cells. However, as osteosarcoma cells express EGFR, further studies are necessary to explore the potential of other therapeutic agents targeting EGFR.

Citations

Citations to this article as recorded by

PD-L1, STAT3, IL6, and EGFR Immunoexpressions in High-Grade Osteosarcoma
Nayla Rahmadiani, Eviana Norahmawati, Agustina Tri Endharti, Ailen Oktaviana Hambalie, Satria Pandu Persada Isma, Raffaele Vitiello
Advances in Orthopedics.2024; 2024: 1. CrossRef
Optimizing near infrared laser irradiation and photosensitizer accumulation period for indocyanine green-mediated photodynamic therapy in breast cancer xenografts: a focus on treatment and characterization
Hasim Ozgur Tabakoglu, Tuğba Kiriş Aydoğan, Ayşenur Kiriş, Saadet Akbulut
Lasers in Medical Science.2024;[Epub] CrossRef
EGFR-targeting peptide conjugated polymer–lipid hybrid nanoparticles for delivery of salinomycin to osteosarcoma
Longhai Du, Yanlong Xu, Binxu Han, Yu Wang, Qingmin Zeng, Minghao Shao, Zuochong Yu
Journal of Cancer Research and Therapeutics.2023; 19(6): 1544. CrossRef
Epidermal growth factor signalling pathway in endochondral ossification: an evidence-based narrative review
L. Mangiavini, G. M. Peretti, B. Canciani, N. Maffulli
Annals of Medicine.2022; 54(1): 37. CrossRef
Synergistic effect of growth factor receptor-bound protein 2/epidermal growth factor receptor dual-targeting peptide inhibitor and salinomycin on osteosarcoma
Zuochong Yu, Yanlong Xu, Longhai Du, Fan Zhang, Minghao Shao, Lin Xie, Guoping Cai, Feizhou Lyu
Journal of Cancer Research and Therapeutics.2022; 18(2): 352. CrossRef
Stattic sensitizes osteosarcoma cells to epidermal growth factor receptor inhibitors via blocking the interleukin 6-induced STAT3 pathway
Shenglin Wang, Yunqing Wang, Zhen Huang, Hongxiang Wei, Xinwen Wang, Rongkai Shen, Wenbin Lan, Guangxian Zhong, Jianhua Lin
Acta Biochimica et Biophysica Sinica.2021; 53(12): 1670. CrossRef
Afatinib is active in osteosarcoma in osteosarcoma cell lines
Marlid Cruz-Ramos, Yessica Zamudio-Cuevas, Daniel Medina-Luna, Karina Martínez-Flores, Gabriela Martínez-Nava, Javier Fernández-Torres, Alberto López-Reyes, Flavio Solca
Journal of Cancer Research and Clinical Oncology.2020; 146(7): 1693. CrossRef
The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas
Xiaochun Wang, Reichelle X. Yeo, Philip J. Hogg, David Goldstein, Philip Crowe, Pierre J. Dilda, Jia-Lin Yang
Oncotarget.2020; 11(1): 46. CrossRef
Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies
Ingrid Lilienthal, Nikolas Herold
International Journal of Molecular Sciences.2020; 21(18): 6885. CrossRef
Prospects for NK Cell Therapy of Sarcoma
Mieszko Lachota, Marianna Vincenti, Magdalena Winiarska, Kjetil Boye, Radosław Zagożdżon, Karl-Johan Malmberg
Cancers.2020; 12(12): 3719. CrossRef
Advanced development of ErbB family-targeted therapies in osteosarcoma treatment
Wei Wang, Hua-fu Zhao, Teng-fei Yao, Hao Gong
Investigational New Drugs.2019; 37(1): 175. CrossRef
The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells
Tian Wang, Dexing Wang, Lian Zhang, Ping Yang, Jing Wang, Qi Liu, Fei Yan, Feng Lin
Journal of Experimental & Clinical Cancer Research.2019;[Epub] CrossRef
Interpretation of Tongue Squamous Cell Carcinoma via Protein-Protein Interaction Network Construction and Analysis
Mona Zamanian Azodi, Mostafa Rezaei-Tavirani, Majid Rezaei-Tavirani, Vahid Mansouri, Reza Vafaee
International Journal of Cancer Management.2018;[Epub] CrossRef
EGFR is required for FOS‐dependent bone tumor development via RSK2/CREB signaling
Markus Linder, Elisabeth Glitzner, Sriram Srivatsa, Latifa Bakiri, Kazuhiko Matsuoka, Parastoo Shahrouzi, Monika Dumanic, Philipp Novoszel, Thomas Mohr, Oliver Langer, Thomas Wanek, Markus Mitterhauser, Erwin F Wagner, Maria Sibilia
EMBO Molecular Medicine.2018;[Epub] CrossRef
Prognostic significance of the expression of HER family members in primary osteosarcoma
Sheng‑Lin Wang, Guang‑Xian Zhong, Xin‑Wen Wang, Feng‑Qiang Yu, Dan‑Feng Weng, Xin‑Xing Wang, Jian‑Hua Lin
Oncology Letters.2018;[Epub] CrossRef
Effects of epidermal growth factor receptor kinase inhibition on radiation response in canine osteosarcoma cells
Fernanda B. Mantovani, Jodi A. Morrison, Anthony J. Mutsaers
BMC Veterinary Research.2016;[Epub] CrossRef
Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma
Sara Westrøm, Tina B. Bønsdorff, Nasir Abbas, Øyvind S. Bruland, Thora J. Jonasdottir, Gunhild M. Mælandsmo, Roy H. Larsen, Salvatore V Pizzo
PLOS ONE.2016; 11(10): e0165382. CrossRef
Osteoblast dysfunctions in bone diseases: from cellular and molecular mechanisms to therapeutic strategies
Pierre J. Marie
Cellular and Molecular Life Sciences.2015; 72(7): 1347. CrossRef
Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
Aude I. Ségaliny, Marta Tellez-Gabriel, Marie-Françoise Heymann, Dominique Heymann
Journal of Bone Oncology.2015; 4(1): 1. CrossRef
EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance
Florian Sevelda, Lisa Mayr, Bernd Kubista, Daniela Lötsch, Sushilla van Schoonhoven, Reinhard Windhager, Christine Pirker, Michael Micksche, Walter Berger
Journal of Experimental & Clinical Cancer Research.2015;[Epub] CrossRef
Amphiregulin enhances intercellular adhesion molecule-1 expression and promotes tumor metastasis in human osteosarcoma
Ju-Fang Liu, Ya-Ting Tsao, Chun-Han Hou
Oncotarget.2015; 6(38): 40880. CrossRef
ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib
Jiani Liu, Jiangxue Wu, Ling Zhou, Changchuan Pan, Yi Zhou, Wuying Du, Jie-min Chen, Xiaofeng Zhu, Jingnan Shen, Shuai Chen, Ran-yi Liu, Wenlin Huang
Oncotarget.2015; 6(25): 21341. CrossRef
Molecular profiling of childhood cancer: Biomarkers and novel therapies
Federica Saletta, Carol Wadham, David S. Ziegler, Glenn M. Marshall, Michelle Haber, Geoffrey McCowage, Murray D. Norris, Jennifer A. Byrne
BBA Clinical.2014; 1: 59. CrossRef
ErbB Receptors as Prognostic and Therapeutic Drug Targets in Bone and Soft Tissue Sarcomas
Hongsheng Wang, Qingbo Yang, Zeze Fu, Dongqing Zuo, Yingqi Hua, Zhengdong Cai
Cancer Investigation.2014; 32(10): 533. CrossRef
Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models
Bérengère Gobin, Gatien Moriceau, Benjamin Ory, Céline Charrier, Régis Brion, Frederic Blanchard, Françoise Redini, Dominique Heymann, Gerard Roel Rutteman
PLoS ONE.2014; 9(3): e90795. CrossRef
Focal Chromosomal Copy Number Aberrations Identify CMTM8 and GPR177 as New Candidate Driver Genes in Osteosarcoma
Joeri Both, Oscar Krijgsman, Johannes Bras, Gerard R. Schaap, Frank Baas, Bauke Ylstra, Theo J. M. Hulsebos, David Loeb
PLoS ONE.2014; 9(12): e115835. CrossRef
Gefitinib and Luteolin Cause Growth Arrest of Human Prostate Cancer PC-3 Cells via Inhibition of Cyclin G-Associated Kinase and Induction of miR-630
Minami A. Sakurai, Yuki Ozaki, Daisuke Okuzaki, Yoko Naito, Towa Sasakura, Ayumi Okamoto, Hiroe Tabara, Takao Inoue, Man Hagiyama, Akihiko Ito, Norikazu Yabuta, Hiroshi Nojima, Ichiro Aoki
PLoS ONE.2014; 9(6): e100124. CrossRef
Clinical Predictive Value of Serum Angiogenic Factor in Patients with Osteosarcoma
Zhe Chen, Qi-Xin Chen, Zhao-Yang Hou, Jiong Hu, Yan-Guang Cao
Asian Pacific Journal of Cancer Prevention.2012; 13(9): 4823. CrossRef

11,581 View
79 Download
28 Crossref

Assessment of Chemotherapy Response Using FDG-PET in Pediatric Bone Tumors: A Single Institution Experience: Dong Hwan Kim, Seung Yeon Kim, Hyeon Jeong Lee, Bong Sup Song, Dong Ho Kim, Joong Bum Cho, Jung Sub Lim, Jun Ah Lee; Cancer Res Treat. 2011;43(3):170-175. Published online September 30, 2011; DOI: https://doi.org/10.4143/crt.2011.43.3.170

Abstract PDF PubReader ePub

PURPOSE
Response to neo-adjuvant chemotherapy is an important prognostic factor for osteosarcoma (OS) and the Ewing sarcoma family of tumors (ESFT). [F-18]-fluorodeoxy-D-glucose (FDG)-positron emission tomography (PET) is a non-invasive imaging modality that predicts histologic response to chemotherapy of various malignancies; however, limited data exist about the usefulness of FDG-PET in predicting the histologic response of pediatric bone tumors to chemotherapy. We analyzed the FDG-PET imaging characteristics of pediatric bone tumors and determined the association with response to chemotherapy.
MATERIALS AND METHODS
Pediatric patients with OS (n=19) or ESFT (n=17) were evaluated for FDG-PET standard uptake values before (SUV1) and after (SUV2) chemotherapy. The relationship to the chemotherapy response was assessed by histopathology in surgically-excised tumors. A complete data set (SUV1, SUV2, and histologic response) was available in 23 patients.
RESULTS
While the mean SUV1s were not different between patients with OSs and ESFTs (9.44 vs. 6.07, p=0.24), the SUV2s were greater in the patients with OSs than ESFTs (4.55 vs. 1.66, p=0.01). The ratios of SUV2-to-SUV1 (SUV2 : SUV1) were 0.65 and 0.35 for OS and ESFT, respectively (p=0.08). All of the patients with ESFTs and 47% of the patients with OS had a favorable histologic response to chemotherapy. The SUV2 : 1 [(SUV1-SUV2)/SUV1]> or =0.5 and SUV2< or =2.5 were related to favorable histologic responses to chemotherapy; the sensitivity and specificity of SUV2 : 1 at 0.5 and SUV2 at 2.5 were 93% and 88%, and 88% and 78%, respectively.
CONCLUSION
FDG-PET can be used as a non-invasive surrogate to predict response to chemotherapy in children with bone tumors.

Citations

Citations to this article as recorded by

18F-FDG PET/CT in the Management of Osteosarcoma
Chiwoo Oh, Michael W. Bishop, Steve Y. Cho, Hyung-Jun Im, Barry L. Shulkin
Journal of Nuclear Medicine.2023; 64(6): 842. CrossRef
[18F]FDG PET/CT quantitative parameters for the prediction of histological response to induction chemotherapy and clinical outcome in patients with localised bone and soft-tissue Ewing sarcoma
Alessio Annovazzi, Virginia Ferraresi, Vincenzo Anelli, Renato Covello, Sabrina Vari, Carmine Zoccali, Roberto Biagini, Rosa Sciuto
European Radiology.2021; 31(9): 7012. CrossRef
Different 18F‐FDG PET parameters for the prediction of histological response to neoadjuvant chemotherapy in pediatric Ewing sarcoma family of tumors
Gihan El‐Hennawy, Hosna Moustafa, Walid Omar, Naglaa Elkinaai, Ahmad Kamel, Iman Zaki, Nesma Farid, Esraa El‐Kholy
Pediatric Blood & Cancer.2020;[Epub] CrossRef
Sarcomes osseux
J.L. Albérini, P.Y. Salaün
Médecine Nucléaire.2019; 43(1): 138. CrossRef
Diagnostic Accuracy of 18F-FDG PET/CT in the Staging and Assessment of Response to Chemotherapy in Children With Ewing Sarcoma
Antonio Ruggiero, Valerio Lanni, Alberto Librizzi, Palma Maurizi, Giorgio Attinà, Stefano Mastrangelo, Alessandro Giordano, Riccardo Riccardi
Journal of Pediatric Hematology/Oncology.2018; 40(4): 277. CrossRef
The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence
Andrea Angelini, Francesco Ceci, Paolo Castellucci, Tiziano Graziani, Giulia Polverari, Giulia Trovarelli, Emanuela Palmerini, Stefano Ferrari, Stefano Fanti, Pietro Ruggieri
European Journal of Nuclear Medicine and Molecular Imaging.2017; 44(10): 1712. CrossRef
PET/CT of Osteosarcoma and Ewing Sarcoma
Colleen M. Costelloe, Hubert H. Chuang, Najat C. Daw
Seminars in Roentgenology.2017; 52(4): 255. CrossRef
Qualitative and Semi-Quantitative 18-F FDG PET/CT for Osteosarcoma: A Review
Lorenzo Nardo, Michelle Zhang, Luca Facchetti, Benjamin L. Franc
Current Radiology Reports.2017;[Epub] CrossRef
Tumour hypoxia: lessons learnt from preclinical imaging
Isabella Raccagni, Silvia Valtorta, Rosa Maria Moresco, Sara Belloli
Clinical and Translational Imaging.2017; 5(5): 407. CrossRef
Assessment of response to treatment in paediatric bone sarcomas by means of PET imaging
Natale Quartuccio, Byung Hyun Byun, Pierpaolo Alongi, Federico Caobelli, Chang-Bae Kong, Sang Moo Lim, Angelina Cistaro
Clinical and Translational Imaging.2016; 4(1): 41. CrossRef
Modern Methods of Visualization in Diagnosis, Staging and Elaboration of Treatment Tactics for Primary Malignant Bone Tumors. Part I
G. N. Machak, A. K. Morozov, A. I. Snetkov, I. N. Karpov, N. V. Kochergina, A. B. Bludov, A. D. Ryzhkov
Vestnik travmatologii i ortopedii imeni N.N. Priorova.2016; (3): 53. CrossRef
Modern Methods of Visualization in Diagnosis, Staging and Elaboration of Treatment Tactics for Primary Malignant Bone Tumors. Part I
G. N Machak, A. K Morozov, A. I Snetkov, I. N Karpov, N. V Kochergina, A. B Bludov, A. D Ryzhkov
N.N. Priorov Journal of Traumatology and Orthopedics.2016; 23(3): 53. CrossRef
Radiotherapy and gemcitabine–docetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma
Jun Ah Lee, Eun Kyung Paik, Juhee Seo, Dong Ho Kim, Jung Sub Lim, Ji Young Yoo, Mi-Sook Kim
Japanese Journal of Clinical Oncology.2015; : hyv171. CrossRef
Tumor‐to‐background Ratio to Predict Response to Chemotherapy of Osteosarcoma Better than Standard Uptake Values
Jin‐peng He, Yun Hao, Mi Li, Jiang Wang, Feng‐jin Guo
Orthopaedic Surgery.2014; 6(2): 145. CrossRef
Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: Current hurdles and future perspectives
Emmy D.G. Fleuren, Yvonne M.H. Versleijen-Jonkers, Otto C. Boerman, Winette T.A. van der Graaf
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2014; 1845(2): 266. CrossRef
FDG PET/CT of Primary Bone Tumors
Colleen M. Costelloe, Hubert H. Chuang, John E. Madewell
American Journal of Roentgenology.2014; 202(6): W521. CrossRef
Atypical growth on MRI in a case of Ewing’s sarcoma despite lower SUV on PET
Zachary Sanford, Stanford Israelsen, Rajesh Sehgal, Felix H. Cheung
Skeletal Radiology.2014; 43(6): 819. CrossRef
Characterization of Different Osteosarcoma Phenotypes by PET Imaging in Preclinical Animal Models
Carmen Campanile, Matthias J.E. Arlt, Stefanie D. Krämer, Michael Honer, Ana Gvozdenovic, Patrick Brennecke, Cindy R. Fischer, Adam A. Sabile, Adrienne Müller, Simon M. Ametamey, Walter Born, Roger Schibli, Bruno Fuchs
Journal of Nuclear Medicine.2013; 54(8): 1362. CrossRef
Promise and pitfalls of quantitative imaging in oncology clinical trials
Brenda F. Kurland, Elizabeth R. Gerstner, James M. Mountz, Lawrence H. Schwartz, Christopher W. Ryan, Michael M. Graham, John M. Buatti, Fiona M. Fennessy, Edward A. Eikman, Virendra Kumar, Kenneth M. Forster, Richard L. Wahl, Frank S. Lieberman
Magnetic Resonance Imaging.2012; 30(9): 1301. CrossRef
18F NaF PET/CT in the Assessment of Malignant Bone Disease
Camila Mosci, Andrei Iagaru
PET Clinics.2012; 7(3): 263. CrossRef
The Role of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Assessing the Response to Neoadjuvant Treatment in Patients with Osteosarcoma
Carmelo Caldarella, Marco Salsano, Maria Antonietta Isgrò, Giorgio Treglia
International Journal of Molecular Imaging.2012; 2012: 1. CrossRef

12,467 View
71 Download
21 Crossref

Case Report

Two Pediatric Osteosarcoma Cases with Delayed Methotrexate Excretion: Its Clinical Course and Management: Kang Min Lee, Hee Woo Lee, Seung Yeon Kim, Hyeon Jeong Lee, Dong Hwan Kim, Joongbum Cho, Dong Ho Kim, Jung Sub Lim, Jin Kyung Lee, Jun Ah Lee; Cancer Res Treat. 2011;43(1):67-70. Published online March 31, 2011; DOI: https://doi.org/10.4143/crt.2011.43.1.67

Abstract PDF PubReader ePub

High-dose methotrexate (MTX) chemotherapy extends the duration of hospitalization and introduces the risks of serious complications related to delayed MTX excretion. The treatment of delayed MTX excretion is largely dependent on invasive measures such as hemodialysis because the clinical data regarding the efficacy or safety of carboxypetidase G2 is limited. We report here on the cases of two pediatric osteosarcoma patients with delayed MTX excretion and who were successfully managed using supportive measures. Potential life-threatening complications were prevented by administering high doses of leucovorin.

Citations

Citations to this article as recorded by

The Role of Single Nucleotide Polymorphisms in Transporter Proteins and the Folate Metabolism Pathway in Delayed Methotrexate Excretion: A Case Report and Literature Review
Jun Wang, Yue-Tao Zhao, Meng-Jiao Sun, Feng Chen, Hong-Li Guo
Pharmacogenomics and Personalized Medicine.2022; Volume 15: 919. CrossRef
Toxicité rénale des anticancéreux
Blandine Aloy, Nicolas Janus, Corine Isnard-Bagnis, Gilbert Deray, Vincent Launay-Vacher
Néphrologie & Thérapeutique.2021; 17(7): 553. CrossRef
Delayed High-dose Methotrexate Excretion and Influencing Factors in Osteosarcoma Patients
Wei Zhang, Qing Zhang, Ting-Ting Zheng, Jian-Cun Zhen, Xiao-Hui Niu
Chinese Medical Journal.2016; 129(21): 2530. CrossRef

8,847 View
53 Download
3 Crossref

Original Articles

The Survival of Osteosarcoma Patients 10 Years Old or Younger Is Not Worse than the Survival of Older Patients: A Retrospective Analysis: Jun Ah Lee, Dong Ho Kim, Jung Sub Lim, Kyung Duk Park, Won Seok Song, Soo-Yong Lee, Dae-Geun Jeon; Cancer Res Treat. 2007;39(4):160-164. Published online December 31, 2007; DOI: https://doi.org/10.4143/crt.2007.39.4.160

Abstract PDF PubReader ePub

Purpose

This study aimed to assess whether a young age at the time of diagnosis with osteosarcoma has value to predict the prognosis.

Materials and Methods

Sixty-seven children with stage II osteosarcoma were stratified according to the age of 10. There were 32 preadolescents (≤10 years) and 35 adolescents (10<age≤15 years). The patients were analyzed for their clinical characteristics, the histologic response to preoperative chemotherapy, event-free survival (EFS) and the patterns of relapse.

Results

After a median follow-up of 54 months (range: 6~153 months), the 5-year EFS of the preadolescent and adolescent groups was 64.5±9.3% and 58.2±9.1%, respectively, and age did not have any statistical significance for survival (p=0.55). Cox regression analysis revealed that both the serum level of alkaline phosphatase and the histologic response to preoperative chemotherapy were significantly related to survival of the 67 patients. Those patients aged less than 7 years responded poorly to preoperative chemotherapy and their rate of amputation was 43%. However, their 5-year EFS was not statistically different from the older patients (57.1±18.7 vs 67.7±6.3%, respectively, p=0.58).

Conclusions

We could not find any statistical difference in the clinical characteristics and survival from osteosarcoma for the preadolescents and adolescents, so the current approach of having the same protocol for both groups of patients seems to be reasonable.

Citations

Citations to this article as recorded by

Tumor necrosis drives prognosis in osteosarcoma: No difference in chemotherapy response and survival between chondroblastic and osteoblastic osteosarcoma
Neel Patel, Joseph O. Werenski, Marcos R. Gonzalez, Marilee J. Clunk, Meagan R. McCadden, Alexis Richard, Ivan Chebib, Yin P. Hung, G. Petur Nielsen, Santiago A. Lozano-Calderon
Surgical Oncology.2024; 57: 102155. CrossRef
Limb salvage surgery has a higher complication rate than amputation but is still beneficial for patients younger than 10 years old with osteosarcoma of an extremity
Yoichi Kaneuchi, Shinichirou Yoshida, Tomohiro Fujiwara, Scott Evans, Adesegun Abudu
Journal of Pediatric Surgery.2022; 57(11): 702. CrossRef
Molecular profiling of osteosarcoma in children and adolescents from different age groups using a next-generation sequencing panel
G.M. Guimarães, F. Tesser-Gamba, A.S. Petrilli, C.R.P. Donato-Macedo, M.T.S. Alves, F.T. de Lima, R.J. Garcia-Filho, R. Oliveira, S.R.C. Toledo
Cancer Genetics.2021; 258-259: 85. CrossRef
Age and Tumor Location Predict Survival in Nonmetastatic Osteosarcoma in Upper Egypt
Ahmed M. Morsy, Badawy M. Ahmed, Khalid M. Rezk, Islam K.-A. Ramadan, Amir M. Aboelgheit, Hanan A. Eltyb, Osama M. Abd Elbadee, Maha S. El-Naggar
Journal of Pediatric Hematology/Oncology.2020; 42(2): e66. CrossRef
miR-202-5p inhibits the migration and invasion of osteosarcoma cells by targeting ROCK1
Congda Li, Deying Ma, Jinhu Yang, Xiangbo Lin, Bo Chen
Oncology Letters.2018;[Epub] CrossRef
Osteosarcoma in patients younger than 12 years old without metastases have similar prognosis as adolescent and young adults
Sabrina Jeane Prates Eleutério, Andreza Almeida Senerchia, Maria Teresa Almeida, Cecilia Maria Da Costa, Daniel Lustosa, Luiz Mario Calheiros, Jose Henrique Silva Barreto, Algemir Lunardi Brunetto, Carla Renata Pacheco Donato Macedo, Antonio Sergio Petril
Pediatric Blood & Cancer.2015; 62(7): 1209. CrossRef
Prognostic Significance of Serum Alkaline Phosphatase Level in Osteosarcoma: A Meta-Analysis of Published Data
Hai-Yong Ren, Ling-Ling Sun, Heng-Yuan Li, Zhao-Ming Ye
BioMed Research International.2015; 2015: 1. CrossRef
Identification of Osteosarcoma-Related Specific Proteins in Serum Samples Using Surface-Enhanced Laser Desorption/Ionization-Time-of-Flight Mass Spectrometry
Jianli Gu, Jitian Li, Manyu Huang, Zhiyong Zhang, Dongsheng Li, Guoying Song, Xingpo Ding, Wuyin Li
Journal of Immunology Research.2014; 2014: 1. CrossRef
Comparison between preadolescent and adolescent patients with high-grade osteosarcoma in China
Weixiang Qi, Zan Shen, Lina Tang, Aina He, Yumei Yang, Feng Lin, Yang Yao
The Chinese-German Journal of Clinical Oncology.2012; 11(5): 274. CrossRef
The relation of tumour necrosis and survival in patients with osteosarcoma
Xin Li, Adedayo O. Ashana, Vincent M. Moretti, Richard D. Lackman
International Orthopaedics.2011; 35(12): 1847. CrossRef
Osteosarcoma in children 5 years of age or younger at initial diagnosis
Jennifer Worch, Katherine K. Matthay, John Neuhaus, Robert Goldsby, Steven G. DuBois
Pediatric Blood & Cancer.2010; 55(2): 285. CrossRef

9,605 View
59 Download
11 Crossref

Treatment Result of Pediatric Osteosarcoma with Intraarterial Cisplatin: Hyoung Soo Choi, Hyoung Jin Kang, Jun Ah Lee, Hyo Heong Han, Hyeon Jin Park, Eun Sun Yoo, Woo Sun Kim, Hee Young Shin, In One Kim, Sang Hoon Lee, Hyo Seop Ahn, Han Koo Lee; J Korean Cancer Assoc. 1998;30(1):169-177.

Abstract PDF: PURPOSE
This study was performed to determine the outcome after treatment of osteosarcoma with intraarterial cisplatin as a preoperative chematherapy regimen.
MATERIALS AND METHODS
Twenty five patients with extremity osteosarcoma were treated with intraarterial cisplatin at Seoul National University Children's Hospital from January 1987 to April 1996. The dose of cisplatin was 130 mg/m2 and three to six courses were repeated two- to three-week intervals, Systemic doxorubicin was added to six of these patients. This was followed by surgical resection(limb salvage or amputation) and postoperative adjuvant chemotherapy.
RESULTS
Limb-salvage was possible in twenty of these twenty five patients. Pulmonary metastasis was present in five patients at diagnosis and developed later in three patients. In six patients treated with systemic doxorubicin, pulmonary metastasis was absent at diagnosis and during follow-up period. Local recurrence after limb salvage was occurred in one patient and treated with amputation and systemic chemotherapy. Seven patients died from pulmonary metastssis and one from unknown cause. The follow-up duration of these patients was three to eighty eight months(median twenty two months) and the overall five-year survival and event free survival rate were 62.1% and 57.5%, respectively.
CONCLUSION
These data demonstrate that intraarterial cisplatin can be used as an effective regimen preoperatively for pediatric patients with extremity osteosarcoma. The combined use of systemic doxorubicin is expected to improve survival in patients with pulmonary metastasis.

3,067 View
15 Download

First
Prev
Page of 1
Next
Last

Search